ARCHIVES

Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease

This article is from The Cancer Letter archive.

Vol. 35 No. 12 | December 28, 2012

Download PDF Visit The Full Archive

Related Articles

Kington Named Acting NIH Director.

November 14, 2008

BCF Members Miffed When NCI Refuses To Delay New Breast Cancer RFA To Allow Them Chance To Study It

April 8, 1983

Targeting Men At High Risk Finds More Head & Neck Cancer

September 24, 2010

Guest Editorial: Andrew Vickers on PSA Skepticism, Rational and Irrational

October 10, 2014

Phase III Vaccine Trial Fails To Improve Overall Survival

October 25, 2013

NCAB To Hear Program Reviews, Try Again On Act Revisions

October 22, 1976